Natural cytotoxicity triggering receptor 3 (NCR3) (NKp30)

Natural cytotoxicity triggering receptor 3 (NCR3), commonly known as NKp30, is a type I transmembrane glycoprotein and a member of the natural cytotoxicity receptor (NCR) family primarily expressed on mature Natural Killer (NK) cells [UniProt: P59959]. It serves as a critical activating receptor that mediates the recognition and lysis of tumor cells and virus-infected cells by binding to specific ligands such as B7-H6, a member of the B7 family, and BAG6 (also known as BAT3) [PMID: 21616150, PMID: 12426561]. In the context of oncology, NKp30 is vital for immunosurveillance; however, many tumors employ mechanisms to evade this response, such as the shedding of soluble B7-H6 or the production of soluble NKp30 isoforms that act as decoys to inhibit NK cell function [PMID: 21441454]. Therapeutic development focuses on leveraging the NKp30 pathway through chimeric antigen receptor (CAR) technologies, bispecific killer cell engagers (BiKEs), or monoclonal antibodies designed to enhance NK cell-mediated anti-tumor activity [PMID: 30104343]. Understanding the interaction between NKp30 and its diverse ligands is essential for optimizing immunotherapies across various malignancies, including neuroblastoma, gastrointestinal stromal tumors, and certain leukemias.

Other names

NCR3CD337Natural killer cell p30-related protein1C7LY117Activating natural killer receptor p30

NKp30 acts as an activating receptor on NK cells. Upon binding to ligands like B7-H6 (expressed on tumor cells) or BAG6 (released by stressed cells), it associates with ITAM-bearing signaling subunits such as CD3-zeta or Fc-epsilon-RI-gamma. This triggers a signaling cascade involving Syk and ZAP70 kinases, leading to NK cell degranulation, perforin/granzyme release, and production of pro-inflammatory cytokines such as IFN-gamma and TNF-alpha [PMID: 10359811, PMID: 21616150].